Last reviewed · How we verify
NCT06145750: FIRSTLUNG
Implementing Fragmentomics Into Real World Screening IntervenTions to Evaluate Clinical Utility Among Individuals With Elevated Risk for Lung Cancer
NA trial testing Ability to order FirstLook™ in Lung Cancer in 28 participants. Completed in 31 August 2025.
31 August 2025
Quick facts
| Lead sponsor | Delfi Diagnostics Inc. |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 28 |
| Start date | 31 October 2023 |
| Primary completion | 31 August 2025 |
| Estimated completion | 31 August 2025 |
| Sites | 3 locations across United States |
Drugs / interventions tested
- Ability to order FirstLook™
- Continuing Medical Education for Lung Cancer
Conditions studied
- Lung Cancer — all drugs for Lung Cancer →
Sponsor
Delfi Diagnostics Inc. — full company profile →
Who can join
Adults 18 to 80, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to determine whether availability of DNA Evaluation of Fragments for Early Interception (DELFI) Lung Cancer Screening Test, FirstLook™ to practicing physicians affects overall lung cancer screening rates among their patients who are recommended and eligible for screening based on 2021 United States Preventive Services Task Force (USPSTF) but are not up to date with it. DELFI hypothesized that patients in the care of physicians or practice groups who have FirstLook™ will have increased lung screening rates compared to patients in the care of physicians or practice groups who do not have access to FirstLook™.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Clinical Validation of a Cell-Free DNA Fragmentome Assay for Augmentation of Lung Cancer Early Detection.
Mazzone PJ, Bach PB, Carey J, Schonewolf CA, et al · · 2024 · cited 57× · PMID 38829053 · DOI 10.1158/2159-8290.cd-24-0519 -
Exploring the clinical utility of liquid biopsy with cfDNA in cancer: A systematic review.
Ranganathan K, Kurian NS, Goswami HM, Rishi KD, et al · · 2024 · cited 5× · PMID 40027943 · DOI 10.1016/j.jlb.2024.100150 -
Minimally invasive biomarkers for triaging lung nodules-challenges and future perspectives.
Afridi WA, Picos SH, Bark JM, Stamoudis DAF, et al · · 2025 · cited 5× · PMID 39888565 · DOI 10.1007/s10555-025-10247-5 -
Innovations in Early Lung Cancer Detection: Tracing the Evolution and Advancements in Screening.
Cotton LB, Bach PB, Cisar C, Schonewolf CA, et al · · 2024 · cited 5× · PMID 39201053 · DOI 10.3390/jcm13164911
Verify or expand the search:
- PubMed search for NCT06145750
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Lung Cancer
Currently open trials in the same condition.
- NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
- NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
- NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting
Other Delfi Diagnostics Inc. trials
Trials by the same sponsor.
- NCT05306288 — CASCADE-LUNG: Cancer Screening Assay Using DELFI; A Clinical Validation Study in Lung · active not recruiting
- NCT04825834 — DNA Evaluation of Fragments for Early Interception - Lung Cancer Training Study (DELFI-L101 Study) · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06145750 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Delfi Diagnostics Inc.
- Last refreshed: 24 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06145750.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing